deltatrials
Completed PHASE2 NCT00312780

Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy

A Randomized, Double-Blind, Placebo-Controlled Study of XL784 Administered Orally to Subjects With Albuminuria Due to Diabetic Nephropathy

Sponsor: Symphony Evolution, Inc.

Conditions Albuminuria Diabetic Nephropathy
Interventions XL784
Updated 7 times since 2017 Last updated: Feb 22, 2010 Started: Mar 31, 2006 Primary completion: Oct 31, 2007 Completion: Dec 31, 2007

This PHASE2 trial investigates Albuminuria and Diabetic Nephropathy and is currently completed. Symphony Evolution, Inc. leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Symphony Evolution, Inc.
Data source: Symphony Evolution, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States, Baton Rouge, United States, Birmingham, United States, Boston, United States, Charlottesville, United States, Chula Vista, United States, Cleveland, United States, Columbus, United States, Coral Gables, United States, Detroit, United States and 31 more location s